AtriCure (NASDAQ:ATRC) Director Karen Prange Sells 3,564 Shares

AtriCure, Inc. (NASDAQ:ATRC) Director Karen Prange sold 3,564 shares of the company’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total value of $138,283.20. Following the sale, the director owned 22,809 shares of the company’s stock, valued at approximately $884,989.20. The trade was a 13.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Karen Prange also recently made the following trade(s):

• On Wednesday, May 20th, Karen Prange sold 3,000 shares of AtriCure stock. The shares were sold at an average price of $28.65, for a total value of $85,950.00.

AtriCure Trading Up 2.8%

ATRC stock traded up $1.11 during trading on Friday, reaching $40.60. 108,527 shares of the stock traded hands, compared to its average volume of 800,970. The firm has a market capitalization of $2.07 billion, a PE ratio of 193.54 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The business’s 50 day moving average price is $31.98 and its 200-day moving average price is $31.31. AtriCure, Inc. has a 52-week low of $25.36 and a 52-week high of $43.18.

AtriCure (NASDAQ:ATRC) last released its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.The business had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. During the same period in the previous year, the company posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. As a group, sell-side analysts forecast that AtriCure, Inc. will post 0.2 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ATRC has been the topic of a number of research reports. UBS Group cut their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Canaccord Genuity Group increased their target price on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Wall Street Zen lowered AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. Raymond James Financial set a $52.00 price objective on shares of AtriCure in a research note on Tuesday, July 21st. Finally, Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $48.50.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ATRC. Smartleaf Asset Management LLC boosted its stake in AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares during the period. Scotia Capital Inc. grew its stake in shares of AtriCure by 1.2% in the third quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock worth $1,328,000 after acquiring an additional 457 shares during the last quarter. ProShare Advisors LLC raised its stake in AtriCure by 6.6% during the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company’s stock valued at $349,000 after purchasing an additional 543 shares during the last quarter. Captrust Financial Advisors boosted its holdings in AtriCure by 7.9% in the 4th quarter. Captrust Financial Advisors now owns 7,944 shares of the medical device company’s stock valued at $314,000 after purchasing an additional 579 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in AtriCure by 5.3% in the 4th quarter. Mackenzie Financial Corp now owns 13,597 shares of the medical device company’s stock valued at $545,000 after purchasing an additional 683 shares during the period. Institutional investors and hedge funds own 99.11% of the company’s stock.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.